TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Oral Viscous Budesonide Suspension (MB-7) in Subjects With Eosinophilic Esophagitis: A Randomized, Placebo-Controlled, Dose-Ranging Study in Children and Adolescents
Brief Summary: This is a randomized, placebo-controlled, parallel-arm, dose-ranging study in subjects with eosinophilic esophagitis, 2-18 years of age. Eligible subjects will be randomized into one of four treatment groups. The Treatment Period will be 12 weeks during which subjects will visit the clinic at study weeks 0 (Baseline Visit), 2, 4, 8 and 12 (Final Treatment Evaluation) for clinical symptom assessment and safety evaluation (including adverse events and vital signs). All study treatments (active drug and placebo) will be administered orally twice daily during the Treatment Period, once in the morning after breakfast and once in the evening at bedtime.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Budesonide plus Prevacid | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo plus Prevacid | Intervention Type: DRUG; Name: Budesonide plus Prevacid; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo plus Prevacid; Assigned to Arm(s): 2
B: Arm Label: Low dose budesonide tablet; Type: EXPERIMENTAL; Interventions: Drug: low dose budesonide tablet | Arm Label: High dose budesonide tablet; Type: EXPERIMENTAL; Interventions: Drug: high dose budesonide tablet | Arm Label: High dose budesonide suspension; Type: EXPERIMENTAL; Interventions: Drug: high dose budesonide suspension | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: low dose budesonide tablet; Assigned to Arm(s): Low dose budesonide tablet | Intervention Type: DRUG; Name: high dose budesonide tablet; Assigned to Arm(s): High dose budesonide tablet | Intervention Type: DRUG; Name: high dose budesonide suspension; Assigned to Arm(s): High dose budesonide suspension | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Oral Viscous Budesonide (OVB); Type: ACTIVE_COMPARATOR; Interventions: Drug: Oral Viscous Budesonide, Drug: Placebo inhaler | Arm Label: Active Fluticasone MDI; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone MDI, Drug: Placebo slurry | Intervention Type: DRUG; Name: Oral Viscous Budesonide; Assigned to Arm(s): Oral Viscous Budesonide (OVB) | Intervention Type: DRUG; Name: Fluticasone MDI; Assigned to Arm(s): Active Fluticasone MDI | Intervention Type: DRUG; Name: Placebo slurry; Assigned to Arm(s): Active Fluticasone MDI | Intervention Type: DRUG; Name: Placebo inhaler; Assigned to Arm(s): Oral Viscous Budesonide (OVB)
D: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: budesonide | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: budesonide | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: budesonide | Intervention Type: DRUG; Name: budesonide; Assigned to Arm(s): 2, 3, 4 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 1

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Long Term Effects of Lutein/Zeaxanthin and Omega-3- Supplementation on Optical Density of AMD Patients (LUTEGA)
Brief Summary: The primary objective of LUTEGA is it to determine the long term effect (about 1 year) of the supplementation with a fixed combination of lutein/zeaxanthin and omega-3- fatty acids on the optical density (OD) of macular pigment in patients with non- exudative age related maculopathy.

Furthermore, it is to be examined whether changes of the optical density are different dosages dependent. Possible changes of lipofuscin content and effect on drusen in AMD patients are studied. The measurement of optical density of macular pigment uses the 1- wavelength reflection method recording reflection images at 460 nm by a fundus camera. The patients are investigated at baseline and are followed up over one year in four more visits. In addition to the OD- measurement each examination includes standardized visual acuity test (ETDRS), amsler- grid, slit lamp biomicroscopy, fundus photography (color and autofluorescence) and a blood sample.


Options:
A: Arm Label: Lutein/Zeaxanthin; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Lutein/zeaxanthin | Arm Label: DHA/EPA; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: DHA/EPA | Arm Label: Lutein/Zeaxanthin + DHA/EPA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lutein/zeaxanthin and DHA/EPA | Arm Label: Placebo/Control; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Lutein/zeaxanthin; Assigned to Arm(s): Lutein/Zeaxanthin | Intervention Type: DIETARY_SUPPLEMENT; Name: DHA/EPA; Assigned to Arm(s): DHA/EPA | Intervention Type: DRUG; Name: Lutein/zeaxanthin and DHA/EPA; Assigned to Arm(s): Lutein/Zeaxanthin + DHA/EPA
B: Intervention Type: PROCEDURE; Name: Supplementation with fish oil versus placebo; Assigned to Arm(s): N/A
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo capsule | Arm Label: EPA-E 1800 mg/day; Type: EXPERIMENTAL; Interventions: Drug: EPA-E 300 mg capsule | Arm Label: EPA-E 2700 mg/day; Type: EXPERIMENTAL; Interventions: Drug: EPA-E 300 mg capsule | Intervention Type: DRUG; Name: Placebo capsule; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: EPA-E 300 mg capsule; Assigned to Arm(s): EPA-E 1800 mg/day | Intervention Type: DRUG; Name: EPA-E 300 mg capsule; Assigned to Arm(s): EPA-E 2700 mg/day
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Lutein/ Zeaxanthin + Omega-3-FA | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Lutein/ Zeaxanthin + Omega-3-FA | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Lutein/ Zeaxanthin + Omega-3-FA; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Lutein/ Zeaxanthin + Omega-3-FA; Assigned to Arm(s): 2 | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): 3

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Long Term Effects of Lutein/Zeaxanthin and Omega-3- Supplementation on Optical Density of AMD Patients (LUTEGA)
Brief Summary: The primary objective of LUTEGA is it to determine the long term effect (about 1 year) of the supplementation with a fixed combination of lutein/zeaxanthin and omega-3- fatty acids on the optical density (OD) of macular pigment in patients with non- exudative age related maculopathy.

Furthermore, it is to be examined whether changes of the optical density are different dosages dependent. Possible changes of lipofuscin content and effect on drusen in AMD patients are studied. The measurement of optical density of macular pigment uses the 1- wavelength reflection method recording reflection images at 460 nm by a fundus camera. The patients are investigated at baseline and are followed up over one year in four more visits. In addition to the OD- measurement each examination includes standardized visual acuity test (ETDRS), amsler- grid, slit lamp biomicroscopy, fundus photography (color and autofluorescence) and a blood sample.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Lutein/ Zeaxanthin + Omega-3-FA | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Lutein/ Zeaxanthin + Omega-3-FA | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Lutein/ Zeaxanthin + Omega-3-FA; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Lutein/ Zeaxanthin + Omega-3-FA; Assigned to Arm(s): 2 | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): 3
B: Arm Label: N-3 PUFA; Type: EXPERIMENTAL; Interventions: Drug: N-3 Polyunsaturated Fatty Acids | Arm Label: Olive oil; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo: Olive oil | Intervention Type: DRUG; Name: N-3 Polyunsaturated Fatty Acids; Assigned to Arm(s): N-3 PUFA | Intervention Type: DRUG; Name: Placebo: Olive oil; Assigned to Arm(s): Olive oil
C: Intervention Type: DRUG; Name: Triomar™ (omega-3 fatty acids); Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Omega 3 (n-3 PUFA) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Omega 3 (n-3 PUFA); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Validation of a Predictive Model to Estimate the Risk of Conversion to Clinically Significant Macular Edema and/or Vision Loss in Mild Nonproliferative Diabetic Retinopathy in Diabetes Type 2
Brief Summary: This project aims to validate a predictive model of diabetic retinopathy progression to clinically significant macular edema (CSME) needing photocoagulation and/or vision loss. The Coimbra Predictive Model (CPM), based on retinal thickness, microaneurysms number, HbA1C and LDL levels, established on a set of 52 diabetic patients, will be tested on a population of 400 patients/eyes to be enrolled into the study. These patients will perform 2 visits at 6-month interval (V0 and V6) to classify each patient into one of the 3 previously established phenotypes. Two years after (V24) patients will be reexamined. The occurrence of end-points, achieved by the patients, are expected to validate our predictive model.


Options:
A: Arm Label: Modified Early Treatment Diabetic Retinopathy Study (ETDRS); Type: ACTIVE_COMPARATOR; Interventions: Procedure: modified-ETDRS photocoagulation | Arm Label: Mild Macular Grid (MMG); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Mild Macular Grid photocoagulation | Intervention Type: PROCEDURE; Name: modified-ETDRS photocoagulation; Assigned to Arm(s): Modified Early Treatment Diabetic Retinopathy Study (ETDRS) | Intervention Type: PROCEDURE; Name: Mild Macular Grid photocoagulation; Assigned to Arm(s): Mild Macular Grid (MMG)
B: Arm Label: Ranibizumab 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab, Procedure: Laser, Procedure: Sham laser | Arm Label: Ranibizumab 0.5 mg + laser; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab, Procedure: Laser | Arm Label: Laser; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ranibizumab, Procedure: Laser, Drug: Sham to ranibizumab | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Laser, Ranibizumab 0.5 mg, Ranibizumab 0.5 mg + laser | Intervention Type: PROCEDURE; Name: Laser; Assigned to Arm(s): Laser, Ranibizumab 0.5 mg, Ranibizumab 0.5 mg + laser | Intervention Type: PROCEDURE; Name: Sham laser; Assigned to Arm(s): Ranibizumab 0.5 mg | Intervention Type: DRUG; Name: Sham to ranibizumab; Assigned to Arm(s): Laser
C: Arm Label: Ranibizumab 0.3 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab 0.3 mg | Arm Label: Ranibizumab 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab 0.5 mg | Arm Label: Sham injection; Type: SHAM_COMPARATOR; Interventions: Drug: Sham injection | Intervention Type: DRUG; Name: Ranibizumab 0.3 mg; Assigned to Arm(s): Ranibizumab 0.3 mg | Intervention Type: DRUG; Name: Ranibizumab 0.5 mg; Assigned to Arm(s): Ranibizumab 0.5 mg | Intervention Type: DRUG; Name: Sham injection; Assigned to Arm(s): Sham injection
D: Arm Label: MNPDR; Type: N/A; Interventions: N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Randomised, Double-Blind, Multicentre, Parallel-Group, Placebo- and Active-Controlled, Dose-Optimisation Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)
Brief Summary: The main aim of this study is to see if giving LDX to children and adolescents aged 6-17 years with ADHD decreases symptoms of ADHD.


Options:
A: Arm Label: Methylphenidate Transdermal System; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate Transdermal System | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Concerta; Type: ACTIVE_COMPARATOR; Interventions: Drug: Concerta | Intervention Type: DRUG; Name: Methylphenidate Transdermal System; Assigned to Arm(s): Methylphenidate Transdermal System | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Concerta; Assigned to Arm(s): Concerta
B: Intervention Type: DRUG; Name: methylphenidate hydrochloride; Assigned to Arm(s): N/A
C: Arm Label: Lisdexamfetamine Dimesylate (LDX); Type: EXPERIMENTAL; Interventions: Drug: Lisdexamfetamine Dimesylate (LDX) | Arm Label: Methylphenidate Hydrochloride; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate Hydrochloride | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lisdexamfetamine Dimesylate (LDX); Assigned to Arm(s): Lisdexamfetamine Dimesylate (LDX) | Intervention Type: DRUG; Name: Methylphenidate Hydrochloride; Assigned to Arm(s): Methylphenidate Hydrochloride | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: clonidine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: methylphenidate | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: clonidine, Drug: methylphenidate | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: clonidine; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: methylphenidate; Assigned to Arm(s): 2, 3 | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): 4

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Randomised, Double-Blind, Multicentre, Parallel-Group, Placebo- and Active-Controlled, Dose-Optimisation Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)
Brief Summary: The main aim of this study is to see if giving LDX to children and adolescents aged 6-17 years with ADHD decreases symptoms of ADHD.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Vyvanse (lisdexamfetamine dimesylate) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Vyvanse (lisdexamfetamine dimesylate); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: Methylphenidate, Dexamphetamine, Placebo; Type: EXPERIMENTAL; Interventions: Drug: Methylphenidate, Drug: Placebo, Drug: Dextroamphetamine | Intervention Type: DRUG; Name: Methylphenidate; Assigned to Arm(s): Methylphenidate, Dexamphetamine, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Methylphenidate, Dexamphetamine, Placebo | Intervention Type: DRUG; Name: Dextroamphetamine; Assigned to Arm(s): Methylphenidate, Dexamphetamine, Placebo
C: Arm Label: Lisdexamfetamine Dimesylate (LDX, SPD489); Type: ACTIVE_COMPARATOR; Interventions: Drug: LDX | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: LDX; Assigned to Arm(s): Lisdexamfetamine Dimesylate (LDX, SPD489) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Lisdexamfetamine Dimesylate (LDX); Type: EXPERIMENTAL; Interventions: Drug: Lisdexamfetamine Dimesylate (LDX) | Arm Label: Methylphenidate Hydrochloride; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate Hydrochloride | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lisdexamfetamine Dimesylate (LDX); Assigned to Arm(s): Lisdexamfetamine Dimesylate (LDX) | Intervention Type: DRUG; Name: Methylphenidate Hydrochloride; Assigned to Arm(s): Methylphenidate Hydrochloride | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Randomised, Double-Blind, Multicentre, Parallel-Group, Placebo- and Active-Controlled, Dose-Optimisation Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)
Brief Summary: The main aim of this study is to see if giving LDX to children and adolescents aged 6-17 years with ADHD decreases symptoms of ADHD.


Options:
A: Arm Label: 10 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate Hydrochloride Extended Release Capsules | Arm Label: 15 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate Hydrochloride Extended Release Capsules | Arm Label: 20 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate Hydrochloride Extended Release Capsules | Arm Label: 40 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate Hydrochloride Extended Release Capsules | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Methylphenidate HCl ER Capsules (10, 15, 20, 40, 50 or 60 mg); Type: EXPERIMENTAL; Interventions: Drug: Methylphenidate Hydrochloride Extended Release Capsules | Intervention Type: DRUG; Name: Methylphenidate Hydrochloride Extended Release Capsules; Assigned to Arm(s): 10 mg, 15 mg, 20 mg, 40 mg, Methylphenidate HCl ER Capsules (10, 15, 20, 40, 50 or 60 mg) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Lisdexamfetamine Dimesylate (LDX); Type: EXPERIMENTAL; Interventions: Drug: Lisdexamfetamine Dimesylate (LDX) | Arm Label: Methylphenidate Hydrochloride; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate Hydrochloride | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lisdexamfetamine Dimesylate (LDX); Assigned to Arm(s): Lisdexamfetamine Dimesylate (LDX) | Intervention Type: DRUG; Name: Methylphenidate Hydrochloride; Assigned to Arm(s): Methylphenidate Hydrochloride | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: N/A
D: Arm Label: Medication Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vyvanse, Drug: Methylphenidate | Arm Label: Behavioral Parent Training Arm; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Behavioral Parent Training | Intervention Type: DRUG; Name: Vyvanse; Assigned to Arm(s): Medication Arm | Intervention Type: BEHAVIORAL; Name: Behavioral Parent Training; Assigned to Arm(s): Behavioral Parent Training Arm | Intervention Type: DRUG; Name: Methylphenidate; Assigned to Arm(s): Medication Arm

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: PERL 4: Promoting Effective Recovery From Labor
Brief Summary: The primary goal of this project is to determine the efficacy of an antenatal Bladder Health class to prevent UI in a diverse sample of African American, Caucasian, and Hispanic childbearing women. The determination of efficacy will be made at 12-months post index birth, a time point that is a traditional benchmark of recovery from childbirth, using UI incidence/severity as the primary outcome.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Solifenacin succinate | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Simplified bladder training | Intervention Type: DRUG; Name: Solifenacin succinate; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Simplified bladder training; Assigned to Arm(s): 2
B: Intervention Type: BEHAVIORAL; Name: Bladder Health Class consisting of 6 weekly group sessions; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Practice PFMT and BT; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Clinic examination for pelvic muscle function; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Record keeping in 3-day voiding diary; Assigned to Arm(s): N/A
C: Arm Label: Group 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Structured training and leaflet | Arm Label: Group 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Structured training | Arm Label: Group 3; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Leaflet | Arm Label: Group 4; Type: SHAM_COMPARATOR; Interventions: Behavioral: Control Group | Intervention Type: BEHAVIORAL; Name: Structured training and leaflet; Assigned to Arm(s): Group 1 | Intervention Type: BEHAVIORAL; Name: Structured training; Assigned to Arm(s): Group 2 | Intervention Type: BEHAVIORAL; Name: Leaflet; Assigned to Arm(s): Group 3 | Intervention Type: BEHAVIORAL; Name: Control Group; Assigned to Arm(s): Group 4
D: Arm Label: 1 Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care | Arm Label: 2 Bladder Health Class; Type: EXPERIMENTAL; Interventions: Behavioral: Bladder Health class | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): 1 Usual Care | Intervention Type: BEHAVIORAL; Name: Bladder Health class; Assigned to Arm(s): 2 Bladder Health Class

Answer: D